NTLA Stock Recent News
NTLA LATEST HEADLINES
Cathie Wood's biggest bet in her healthcare fund is on a gene editing company. Gene editing has the potential to offer functional cures for serious diseases, so it could be a gamechanger.
Wall Street analysts have high hopes for Intellia Therapeutics stock. The company's late-stage pipeline programs are shaping up nicely.
Intellia Therapeutics, Inc. (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, will present its fourth quarter and full-year 2023 financial results and operational highlights in a conference call on February 22, 2024, at 8 a.m. ET.
Gene editing is revolutionizing medicine. For example, just weeks ago, the U.S. Federal Drug Administration approved a new gene-editing treatment for sickle cell disease and transfusion-dependent beta-thalassemia, a genetic disorder that prevents the production of hemoglobin in the blood and requires regular blood transfusions.
With patience, some of the most undervalued biotech stocks can create massive wealth. Look at ACADIA Pharmaceuticals (NASDAQ: ACAD ), for example.
Cathie Wood purchased shares of Palantir, Tesla, and Intellia Therapeutics yesterday. She tends to buy some of her favorite stocks when they take a hit, but Palantir soared 31% on Tuesday after a well-received financial update.
Some of the top gene-editing stocks have had immense surge potential. Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.
The S&P 500 has increased about 35% in this new bull market -- but if history is a guide, gains have just gotten started. Past bull markets have lasted much longer than bear markets.
Intellia Therapeutics, Inc. (NTLA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.